73 results about "Methylglyoxal" patented technology

The invention provides a method for improving the synthesis process of Acipimox, which is characterized by carrying out one-pot method on the steps of oxidization, acidification, decarboxylation and oxidization after cyclizing methylglyoxal and o-phenylenediamine which are taken as the original raw materials to directly prepare Acipimox. The method dispenses with intermediate processing, thus greatly simplifying the process steps, and overcomes the defect that the intermediate is easy to oxidize slowly due to multi-step processing, simultaneously utilizes the catalyst for catalytic oxidation in the process of H2O2 oxidation so as to facilitate reaction, improves the reaction yield (66% of overall yield) and is more beneficial to industrial production.

The invention discloses a system and a method for synchronous on-line measurement of concentrations of glyoxal and methylglyoxal in atmosphere. The synchronous on-line measurement of the glyoxal and the methylglyoxal in the atmosphere can be realized based on cavity enhanced absorption spectroscopy technology, a cage structure cavity frame constructed by a cage plate and a fiber rod support is used as a carrier to construct, by two high-reflectivity reflectors, an optical resonant cavity for measurement of characteristic spectral absorption of the glyoxal and the methylglyoxal in the wavelength range of 440-460 nm to quantify the concentrations of the glyoxal and the methylglyoxal in a sampled gas. . The interference of nitrogen dioxide on the glyoxal and the methylglyoxal in a spectrum analysis process is reduced by photolysis of the nitrogen dioxide in the sample gas, the sensitivity and the accuracy of the on-line measurement of the concentrations of the glyoxal and the methylglyoxal can be improved, and the system and the method have the advantages of high temporal-spatial resolution, high sensitivity, high stability, high degree of automation, low detection limit and low cost.

Provided is a method for prediabetes screening by means of methylglyoxal-modified arginine derivative assay, with which it is possible to treat many samples as simply and as safely as with blood sugar assay, and to collect a blood sample taken during a primary health screening in one procedure without imposing any time restraints, complications or risks on the subject. The method for prediabetes screening by means of methylglyoxal-modified arginine derivative assay comprises assaying the methylglyoxal-modified arginine derivative in blood using an assay system which employs an antibody that specifically recognizes methylglyoxal-modified arginine derivative.

The present invention relates to a physicochemically stable pharmaceutical composition, in a unit dose characterized in that it comprises effective amounts of the active ingredients thiamine (Vitamin B1), pyridoxine (Vitamin B6), a flavonoid such as quercetin and a polyphenol such as curcumin, or their pharmaceutically acceptable salts in combination with pharmaceutically acceptable excipients, for the prevention of the formation and / or trapping of advanced glycation end products (glyoxal, methylglyoxal, N-carboxymethyl-lysine, N-carboxyethyl-lysine, pyrraline, pentosidine, lysine dimer, etc.), which can be used in the treatment and / or prevention of complications of diabetes mellitus (diabetic neuropathy, nephropathy and retinopathy).The pharmaceutical composition of the invention is presented orally, preferably in capsule, pill or sachet for oral administration.

The invention discloses a Pictet-Spengler enzyme and an encoding gene and application thereof. The encoding gene nfcbB of the Pictet-Spengler enzyme is as shown in the nucleotide sequence of SEQ ID NO. 1, and NfcbB of the Pictet-Spengler enzyme is as shown in the nucleotide sequence of SEQ ID NO. 2. beta-carboline framework 1-acyl-3-carboxyl-beta-carboline can be produced by constructing recombinant escherichia coli BL21 (DE3) containing the nfcbB gene, and purified NfcbB can catalyze L-tryptophan and pyroracemic aldehyde to react to produce the beta-carboline framework 1-acyl-3-carboxyl-beta-carboline. The discovery and functional identification of the NfcbB have practical guiding significance for the large-scale production of alkaloids, and the NfcbB is applicable to the fields of biology, medicine, fine chemical industry and the like.

The invention provides compositions based on either medicinal honey containing broad spectrum antibacterial activities of peroxide, polyphenols and methylglyoxal, or an effective amount of an active anti-inflammatory ingredient of mineral solids fortified with methylglyoxal antibacterial activity, or a mixture of both for the treatment of wounds; and methods of treating a wound, comprising contacting a wound with any one of the above compositions or a wound dressing containing any one of the above compositions.

The present invention discloses a use of lotus procyanidin as an advanced glycosylation end product formation inhibitor. The drug composition adopting the lotus procyanidin as a main active component comprises the following nature active component extracts, by weight, 70-80% of lotus procyanidin, 10-20% of a synergist such as VE, VC, epigallocatechin gallate (EGCG), cysteine and other ??complexes, and 5-10% of other nature extracts such as a lotus leaf extract, a ginkgo leaf extract and the like. According to the present invention, a high performance liquid chromatography method is adopted to detect a methylglyoxal removing effect of the lotus procyanidin and the main structure unit thereof (catechin), wherein methylglyoxal is an important intermediate substance during an advanced glycosylation end product formation process; a high performance liquid chromatography / multi-stage mass spectrometry method is adopted to identify adducts of four catechin and methylglyoxal and adducts of nine lotus procyanidin and methylglyoxal; and results show that lotus procyanidin provides good inhibition effects for advanced glycosylation end product formation in simulated physiological environments and simulated food systems.

Provided is a method for prediabetes screening by means of methylglyoxal-modified arginine derivative assay, with which it is possible to treat many samples as simply and as safely as with blood sugar assay, and to collect a blood sample taken during a primary health screening in one procedure without imposing any time restraints, complications or risks on the subject. The method for prediabetes screening by means of methylglyoxal-modified arginine derivative assay comprises assaying the methylglyoxal-modified arginine derivative in blood using an assay system which employs an antibody that specifically recognizes methylglyoxal-modified arginine derivative.

The invention discloses a method for generating acetylacetone through an extracellular enzyme reaction, and belongs to the technical field of bioengineering. The method comprises the following steps:1) connecting an acetylacetone lyase mutant gene Dke1<K15Q> to an expression vector to obtain a recombinant vector; 2) transforming the recombinant vector obtained in the step 1) into host bacteria toobtain recombinant bacteria, and performing fermentation culture on the recombinant bacteria to obtain a culture solution; 3) treating the culture solution obtained in the step 2) to obtain an enzymesolution; and 4) mixing the enzyme solution obtained in the step 3) with reaction substrates, and then carrying out a reaction to prepare acetylacetone. According to the method provided by the invention, methylglyoxal and ammonium acetate can be converted into acetylacetone by utilizing the enzyme reaction in vitro, the yield reaches 388.9 mg / L, and a new thought is provided for solving the problem of toxicity inhibition of acetylacetone on cells in a whole-cell synthesis system.

The preparation process of 5-methyl pyrazine-2-carboxylic acid with pyruvic aldehyde and o-diaminobenzene as basic material includes the cyclization in the presence of catalyst, oxidation with inorganic oxidant, acidification with sulfuric acid, decarbolxylation, extraction and separation with butanone, crystallization, drying and crushing. The 5-methyl pyrazine-2-carboxylic acid product has smelting point of 164-172 deg.c. The product is used as the intermediate for the medicine for treating diabetes and hyperlipemia.

The present invention relates to methods and biomarkers for detection, characterization and treatment of conditions associated with methylglyoxal (MG) in biological samples. In particular, the present invention provides compositions and methods for determining diabetic complication onset in a patient through detecting a o-phenylenediamine derivatized MG (2MQ) product as indicative of the presence of MG, impaired fibrinolysis in a patient through detecting a MG modified plasminogen (Pg) product as indicative of impaired fibrinolysis, and the efficacy of metformin (MF) treatment in a patient through detecting IMZ as indicative of a MF / MG product.